Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MyoPAXon in Duchenne Muscular Dystrophy
NCT06692426Phase 1Recruiting
- Sponsor
- Masonic Cancer Center
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label trial of MyoPAXon in Duchenne muscular dystrophy (DMD) (4 arms), sponsored by Masonic Cancer Center. Primary endpoint: Maximal Tolerable Dose at 3 months. Started Mar 2025; status: recruiting.
02
Drugs
MyoPAXon
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT06692426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06692426.